Apolipoprotein B (apoB) testing may offer a more accurate assessment of heart disease risk than traditional LDL cholesterol screening, according to recent medical research. While LDL cholesterol remains the standard marker in routine blood tests, apoB measures the actual number of harmful lipoprotein particles in the bloodstream, providing a more direct evaluation of cardiovascular risk.

Doctors typically monitor LDL levels as the primary indicator for heart disease prevention, but emerging evidence suggests apoB could be superior. Each harmful lipoprotein particle contains one apoB molecule, making the test essentially count these dangerous compounds. This approach captures the overall burden of plaque-producing particles rather than just the cholesterol they carry.

Despite its potential advantages, less than 1% of U.S. adults have been tested for apoB, according to a 2024 study. The American Heart Association currently recommends apoB testing only for patients with high triglycerides, though some cardiologists argue it should be routine for all adults. Insurance coverage varies, with out-of-pocket costs typically around $70 at laboratories.

The growing interest in apoB testing has caught the attention of health influencers and commercial testing companies. Some restaurants, like Sweetgreen, have even partnered with testing firms to promote apoB screening alongside their menus. However, medical experts emphasize that the most pressing issue remains that nearly 25% of eligible adults haven't had any cholesterol screening in the past five years, regardless of which test they use.

Quick Fact: Less than 1% of U.S. adults have been tested for apoB blood protein.